Krüger, Ullrich

[["dc.bibliographiccitation.firstpage","443"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","447"],["dc.bibliographiccitation.volume","301"],["dc.contributor.author","Moessner, Rotraut"],["dc.contributor.author","Stiens, Gerthild"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Schmidt, Diane"],["dc.contributor.author","Platzer, Anja"],["dc.contributor.author","Krueger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T08:27:58Z"],["dc.date.available","2018-11-07T08:27:58Z"],["dc.date.issued","2009"],["dc.description.abstract","Serotonin is a monoamine acting as a neuromediator in the central and peripheral nervous system. Recently, serotonin has also been shown to influence T- and B-cell function. The serotonin transporter is central in the regulation of the serotonergic system and widely expressed on cells of the immune system. A functional length polymorphism in the promoter of the serotonin transporter gene (5-HTTLPR) has been implicated in the genetic background of depression. Psoriasis is a complex disease with a polygenetic inheritance. In light of the role of T-cell mediated inflammation in psoriasis and the increased prevalence of depression in psoriatic patients, we analyzed the 5-HTTLPR polymorphism in 309 patients with psoriasis vulgaris and 315 healthy control individuals. No significant differences in genotype distribution and allele frequencies were found. There was also no difference in the score of the Hamilton Rating Scale for Depression in patients with psoriasis (n = 137) characterized by carriage of different 5-HTTLPR genotypes. These findings argue against a major contribution of the 5-HTTLPR polymorphism to psoriasis susceptibility and the occurrence of depressive symptoms among psoriatic patients."],["dc.description.sponsorship","Deutscher Psoriasis Bund"],["dc.identifier.doi","10.1007/s00403-008-0909-3"],["dc.identifier.isi","000267389100005"],["dc.identifier.pmid","18979110"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3521"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16317"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","101"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Archives of Dermatological Research"],["dc.bibliographiccitation.lastpage","105"],["dc.bibliographiccitation.volume","300"],["dc.contributor.author","Mössner, Rotraut"],["dc.contributor.author","Thaci, Diamant"],["dc.contributor.author","Mohr, Johannes"],["dc.contributor.author","Pätzold, Sylvie"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Krüger, Ullrich"],["dc.contributor.author","Reich, Kristian"],["dc.date.accessioned","2018-11-07T11:17:20Z"],["dc.date.available","2018-11-07T11:17:20Z"],["dc.date.issued","2008"],["dc.description.abstract","Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis. In case reports, positive effects on pustular variants of psoriasis have also been reported. However, paradoxically, manifestation of pustular psoriasis and plaque-type psoriasis has been reported in patients treated with TNF antagonists including infliximab for other indications. Here, we report on 5 patients with chronic plaque-type psoriasis who developed palmoplantar pustulosis during or after discontinuation of infliximab therapy. In two of the five cases, manifestation of palmoplantar pustulosis was not accompanied by worsening of plaque-type psoriasis. Possibly, site-specific factors or a differential contribution of immunological processes modulated by TNF inhibitors to palmoplantar pustulosis and plaque-type psoriasis may have played a role."],["dc.identifier.doi","10.1007/s00403-008-0831-8"],["dc.identifier.isi","000253573300001"],["dc.identifier.pmid","18239925"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/3520"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54781"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","Najko"],["dc.relation.issn","0340-3696"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]